Bio-Path Holdings Inc Sustainability Reports
Bio-Path Holdings, Inc. is a clinical and preclinical stage oncology-focused biotechnology company. It leverages its proprietary DNAbilize liposomal delivery and antisense technology to develop targeted nucleic acid cancer drugs.
Sector: Manufacturing
Country: United States
Exchange: OTC Markets
LEI: 5493000NXNRCVORQVB27
FIGI: BBG001SLNWJ4
4 reports from 2008 to 2023
